Vertex Pharmaceuticals Inc

2 nov 2026, 23:02 UTC

Vertex Pharmaceuticals reported Q3 revenue of $3.44 billion, raised full-year guidance to $13.15 billion-$13.25 billion, and completed the acquisition of Crinetics Pharmaceuticals.

30 okt 2026, 23:26 UTC

Vertex Pharmaceuticals shares advanced modestly in after-market trading, recovering from earlier losses and surpassing Friday's close amid increased momentum.

29 okt 2026, 23:03 UTC

Vertex Pharmaceuticals is trading higher in after-market hours, rebounding from an earlier session low to surpass Thursday's close significantly.

28 okt 2026, 22:03 UTC

Vertex Pharmaceuticals is trading higher in after-market hours, having advanced significantly since Wednesday's close and reached a session high.

27 okt 2026, 23:36 UTC

Vertex Pharmaceuticals is set to report Q3 FY2026 earnings on November 2, with estimated EPS of $0.94 and expected revenue of $3.4 billion.

26 okt 2026, 20:02 UTC

Vertex Pharmaceuticals announces Phase 3 RAINIER results for povetacicept published in the New England Journal of Medicine, with data presented at Kidney Week 2026.

23 okt 2026, 20:08 UTC

Vertex Pharmaceuticals published positive Phase 3 RAINIER results for povetacicept in IgA nephropathy and received FDA acceptance for a Biologics License Application.

22 okt 2026, 23:46 UTC

Vertex Pharmaceuticals Inc shares have seen a slight decline during after-market trading, remaining roughly flat since Thursday's close.

21 okt 2026, 23:01 UTC

Vertex Pharmaceuticals Inc is declining in after-market trading, currently at its lowest point of the day following a sharp drop since Wednesday's close.

20 okt 2026, 23:11 UTC

Vertex Pharmaceuticals Inc is trading lower in after-market hours, having declined since Tuesday's close, despite a brief early-session gain.

19 okt 2026, 22:16 UTC

Vertex Pharmaceuticals Inc shares are modestly higher in after-market trading following fluctuations during the session and a notable decline from earlier peaks.

16 okt 2026, 20:07 UTC

Vertex Pharmaceuticals Inc shares are declining, reversing from an earlier session high and remaining below their 20-day moving average, significantly lower than Thursday's close.

15 okt 2026, 20:03 UTC

Vertex Pharmaceuticals has completed its $10 billion acquisition of Crinetics Pharmaceuticals, contributing to higher shares amid strong performance in the Biotechnology sector.

14 okt 2026, 23:31 UTC

Vertex Pharmaceuticals Inc. is trading modestly higher in after-market hours, recovering from an earlier retreat, and has risen since Wednesday's close.

13 okt 2026, 20:01 UTC

Vertex Pharmaceuticals Inc shares are declining, marked by a significant drop from the opening price and reaching the lowest point of the session.

12 okt 2026, 20:06 UTC

Vertex Pharmaceuticals Inc shares are modestly lower, settling near the lower end of their one-month range and below the 20-day moving average.

9 okt 2026, 20:07 UTC

Vertex Pharmaceuticals presents promising interim data from its ALYFTREK study, showing potential reversal of pancreatic insufficiency in some children with cystic fibrosis.

8 okt 2026, 20:07 UTC

RBC Capital raised the price target on Vertex Pharmaceuticals to $576 from $560 while maintaining an Outperform rating.

7 okt 2026, 19:55 UTC

Vertex Pharmaceuticals Inc is trading modestly higher, having reached an intraday high before retracing, though it remains below its 20-day moving average.

6 okt 2026, 20:06 UTC

Vertex Pharmaceuticals Inc shares are declining amid a broader downturn in the biotechnology sector, marked by five consecutive sessions of losses.

5 okt 2026, 20:06 UTC

Vertex Pharmaceuticals Inc shares fell, continuing a trend of four consecutive sessions lower, despite earlier peaks in the current session.

2 okt 2026, 20:07 UTC

Vertex Pharmaceuticals Inc shares fell to their lowest level since August 2026, reflecting a decline since Thursday's close amid broader market losses.

1 okt 2026, 23:30 UTC

Vertex Pharmaceuticals Inc is trading modestly higher in after-market hours, recovering from earlier declines but remains below its 20-day moving average.

30 sep 2026, 23:05 UTC

Vertex Pharmaceuticals Inc. has advanced modestly in after-market trading, recovering from an earlier session drop and positioning it around the middle of its one-month trading range.

29 sep 2026, 19:36 UTC

Vertex Pharmaceuticals Inc is trading slightly higher, maintaining a narrow cumulative return since Monday, following a low earlier in the day.

28 sep 2026, 21:20 UTC

Vertex Pharmaceuticals Inc is experiencing a notable decline in after-market trading, reaching its lowest cumulative return near the lower end of its one-month trading range.

25 sep 2026, 23:00 UTC

Vertex Pharmaceuticals Inc is trading modestly lower in after-market hours, reflecting a decline since Friday's close following five consecutive higher daily closes.

24 sep 2026, 19:56 UTC

Vertex Pharmaceuticals has acquired Crinetics and launched JOURNAVX, with shares gaining ground despite pulling back from an earlier session high.

23 sep 2026, 23:51 UTC

Vertex Pharmaceuticals Inc saw a modest rise in after-market trading, recovering from a low return shortly after the market closed.

22 sep 2026, 20:02 UTC

Vertex Pharmaceuticals shares are advancing after positive Phase 2b results for inaxaplin, showing significant reductions in urine albumin-to-creatinine ratio in patients.